CVS Health stock holds buy rating at TD Cowen on retail spin report

TD Cowen reiterated its Buy rating and $110 price target on CVS Health, implying roughly 20% upside from $91.41, and estimated a potential $71 billion in proceeds from a sale of the pharmacy and consumer wellness segment using 9x its 2027 adjusted EBITDA estimate. The spin-off report remains unsubstantiated; TD Cowen cited the segment’s return to growth and potential regulatory benefits, and expects a Q3 adjusted EPS beat. The firm also expects management to discuss its 2027 adjusted EPS framework of at least $8.44.

Analysis

The breakup case is an optionality story, not yet a value-realization event. A headline valuation built from a 2027 EBITDA multiple is highly sensitive to the earnings base, separation costs, stranded corporate expense, debt allocation and any discount buyers demand for a standalone retail-pharmacy footprint. It should not be treated as cash proceeds or as proof that CVS’s consolidated valuation gap closes.

The strategic trade-off is easy to miss: separating retail could reduce conflicts tied to CVS’s vertically integrated structure, but it may also weaken the distribution and customer-data loop linking pharmacies, the PBM and the health plan. A weaker integrated proposition could matter more over time than a one-off breakup premium. Meanwhile, the cited decline in CVS’s Medicare Advantage Stars mix creates a separate earnings-quality risk; a Q3 beat would not resolve the 2027 reimbursement and membership economics.

Over days, the earnings report and management’s specificity on the 2027 EPS floor are the catalysts. Over 1–3 months, watch for a board-level process, transaction structure and regulatory detail—not another unsourced report. Over 6–18 months, standalone earnings durability, 340B exposure and MA performance will determine whether separation value is realizable. The contrarian risk is that positive analyst revisions and breakup enthusiasm pull forward upside while the operating proof remains incomplete.

Key Decisions for Investors

• Do not capitalize the reported sum-of-parts estimate as a near-term catalyst. Treat it as a scenario until CVS confirms a process and discloses separation costs, debt allocation, stranded costs and standalone segment earnings.
• Consider a staged long in CVS only after Q3 if management supports the 2027 EPS framework with credible drivers and the health-benefits outlook does not deteriorate. The setup is event-driven, not a buy-the-rumor trade; reduce or exit if guidance weakens or the framework becomes less attainable.
• Use any breakup-driven rally to reassess exposure rather than automatically adding: the thesis is falsified if CVS rules out separation, offers no credible structure/timing, or standalone economics imply value materially below the headline multiple case.
• Track Medicare Advantage Stars, 340B policy and the split between pharmacy growth and GLP-1 bridge activity. A beat concentrated in temporary or nonrecurring drivers, or further deterioration in MA economics, would weaken the medium-term case even if the stock initially reacts positively.